

G. S. Gupta

Animal Lectins: Form, Function and Clinical Applications

Volume 2

G.S. Gupta

Animal Lectins: Form, Function and Clinical Applications

In Collaboration with Anita Gupta
and Rajesh K. Gupta

 Springer

Principal author
G.S. Gupta, Ph. D.
Panjab University
Chandigarh 160014
India

ISBN 978-3-7091-1064-5 ISBN 978-3-7091-1065-2 (eBook)
DOI 10.1007/978-3-7091-1065-2
Springer Wien Heidelberg New York Dordrecht London

Library of Congress Control Number: 2012945422

© Springer-Verlag Wien 2012

This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. Exempted from this legal reservation are brief excerpts in connection with reviews or scholarly analysis or material supplied specifically for the purpose of being entered and executed on a computer system, for exclusive use by the purchaser of the work. Duplication of this publication or parts thereof is permitted only under the provisions of the Copyright Law of the Publisher's location, in its current version, and permission for use must always be obtained from Springer. Permissions for use may be obtained through RightsLink at the Copyright Clearance Center. Violations are liable to prosecution under the respective Copyright Law.

The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

While the advice and information in this book are believed to be true and accurate at the date of publication, neither the authors nor the editors nor the publisher can accept any legal responsibility for any errors or omissions that may be made. The publisher makes no warranty, express or implied, with respect to the material contained herein.

Printed on acid-free paper

Springer is part of Springer Science+Business Media (www.springer.com)

Contents of Volume 2

Part VIII C-Type Lectins: Collectins

22 C-Type Lectins Family	473
Anita Gupta and G.S. Gupta	
22.1 C-Type Lectins Family	473
22.1.1 The C-Type Lectins (CLEC)	473
22.1.2 C-Type Lectin Like Domain (CLRD/CTLD)	473
22.1.3 The CLRD Fold	474
22.1.4 Ligand Binding	477
22.1.5 C-Type Lectin-Like Domains in Model Organisms	477
22.2 Classification of CLRD/CTLD-Containing Proteins	477
22.3 Disulfide Bonds in Lectins and Secondary Structure	478
22.3.1 Arrangement of Disulfide Bonds in CTLDs	478
22.3.2 Functional Role of Disulfides in CTLD of Vertebrates	478
22.4 Collectins	480
22.4.1 Collectins: A Group of Collagenous Type of Lectins	480
References	480
23 Collectins: Mannan-Binding Protein as a Model Lectin	483
Anita Gupta	
23.1 Collectins	483
23.1.1 N-Terminal Region	484
23.1.2 Collagenous Region	484
23.1.3 C-Type Lectin Domain	485
23.1.4 Comparative Genetics of Collagenous Lectins	486
23.1.5 Generalized Functions of Collectins	486
23.2 Human Mannan-Binding Protein	487
23.2.1 Characterization of Serum MBL	487
23.2.2 Gene Structure of MBP	489
23.2.3 Regulation of MBP Gene	490
23.2.4 Structure-Function Relations	491
23.2.5 Functions of MBL	492
23.3 MBP/MBL from Other Species	494
23.3.1 Rodents	494
23.3.2 Primates MBL	495
23.4 Similarity Between C1Q and Collectins/Defense Collagens	495
23.4.1 Structural Similarities	495
23.4.2 Functional Similarities	496
23.4.3 Receptors for Defense Collagens	496
References	496

24 Pulmonary SP-A: Forms and Functions	501
Anita Gupta and Rajesh K. Gupta	
24.1 Pulmonary Surfactant Proteins	501
24.1.1 Pulmonary Surfactant	501
24.1.2 Pulmonary Surfactant Protein A	501
24.2 Structural Properties of SP-A	502
24.2.1 Human SP-A: Domain Structure	502
24.2.2 Structural Biology of Rat SP-A	504
24.2.3 3-D Structure of SP-A Trimer	505
24.2.4 Bovine SP-A	506
24.2.5 SP-A in Other Species	507
24.3 Cell Surface Receptors for SP-A	508
24.4 Interactions of SP-A	509
24.4.1 Protein-Protein Interactions	509
24.4.2 Protein-Carbohydrate Interactions	510
24.4.3 SP-A Binding with Lipids	510
24.5 Functions of SP-A	511
24.5.1 Surfactant Components in Surface Film Formation	511
24.5.2 Recognition and Clearance of Pathogens	512
24.5.3 SP-A: As a Component of Complement System in Lung	513
24.5.4 Modulation of Adaptive Immune Responses by SPs	513
24.5.5 SP-A Stimulates Chemotaxis of AM Φ and Neutrophils	515
24.5.6 SP-A Inhibits sPLA2 and Regulates Surfactant Phospholipid Break-Down	515
24.5.7 SP-A Helps in Increased Clearance of Alveolar DPPC	515
24.5.8 Protection of Type II Pneumocytes from Apoptosis	516
24.5.9 Anti-inflammatory Role of SP-A	516
24.6 Reactive Oxygen and Nitrogen-Induced Lung Injury	518
24.6.1 Decreased Ability of Nitrated SP-A to Aggregate Surfactant Lipids	518
24.7 Non-Pulmonary SP-A	518
24.7.1 SP-A in Epithelial Cells of Small and Large Intestine	518
24.7.2 SP-A in Female Genital Tract and During Pregnancy	519
References	519
25 Surfactant Protein-D	527
Rajesh K. Gupta and Anita Gupta	
25.1 Pulmonary Surfactant Protein-D (SP-D)	527
25.1.1 Human Pulmonary SP-D	528
25.1.2 Rat Lung SP-D	529
25.1.3 Mouse SP-D	530
25.1.4 Bovine SP-D	531
25.1.5 Porcine Lung SP-D	531
25.2 Interactions of SP-D	531
25.2.1 Interactions with Carbohydrates	531
25.2.2 Binding with Nucleic Acids	533
25.2.3 Interactions with Lipids	533
25.3 Structure: Function Relations of Lung SP-D	533
25.3.1 Role of NH ₂ Domain and Collagenous Region	533
25.3.2 Role of NH ₂ -Terminal Cysteines in Collagen Helix Formation	534
25.3.3 D4 (CRD) Domain in Phospholipid Interaction	534

25.3.4	A Three Stranded α -Helical Bundle at Nucleation Site of Collagen Triple-Helix Formation	535
25.3.5	Ligand Binding Amino Acids	535
25.3.6	Ligand Binding and Immune Cell-Recognition	535
25.4	Regulation of Sp-D by Various Factors	536
25.4.1	Glucocorticoids	536
25.4.2	1 α ,25-Dihydroxyvitamin D3	536
25.4.3	Growth Factors	536
25.5	SP-D in Human Fetal and Newborns Lungs	537
25.6	Non-Pulmonary SP-D	537
25.6.1	Human Skin and Nasal Mucosa	537
25.6.2	Digestive Tract, Mesentery, and Other Organs	537
25.6.3	Male Reproductive Tract	538
25.6.4	Female Genital Tract	538
25.7	Functions of Lung SP-D	539
25.7.1	Innate Immunity	539
25.7.2	Effects on Alveolar Macrophages	539
25.7.3	Functions of Neutrophils	540
25.7.4	Protective Role in Allergy and Infection	541
25.7.5	Adaptive Immune Responses	543
25.7.6	Apoptosis	544
25.7.7	Other Effects of SP-D	544
25.8	Oxidative Stress and Hyperoxia	544
	References	545

Part IX C-Type Lectins: Selectins

26	L-Selectin (CD62L) and Its Ligands	553
	G.S. Gupta	
26.1	Cell Adhesion Molecules	553
26.1.1	Selectins	553
26.2	Leukocyte-Endothelial Cell Adhesion Molecule 1 (LECAM-1) (L-Selectin/CD62L or LAM-1)	554
26.2.1	Leukocyte-Endothelial Cell Adhesion Molecule 1 in Humans	554
26.2.2	Gene Structure of L-Selectin	555
26.2.3	Murine PLN Homing Receptor/mLHR3	555
26.3	Functions of L-Selectin	556
26.3.1	Lymphocyte Homing and Leukocyte Rolling and Migration	556
26.3.2	Immune Responses	557
26.4	L-Selectin: Carbohydrate Interactions	559
26.4.1	Glycan-Dependent Leukocyte Adhesion	559
26.5	Cell Surface Ligands for L-Selectin	561
26.5.1	Subsets of Sialylated, Sulfated Mucins of Diverse Origins are Recognized by L-Selectin	561
26.5.2	GlyCAM-1	561
26.5.3	CD34	562
26.5.4	Mucosal Addressin Cell Adhesion Molecule-1 (MAdCAM-1)	563
26.5.5	PSGL-1 Binds L-Selectin	564
26.6	L-Selectin IN Pathological States	564
26.6.1	Gene Polymorphism in L-Selectin	564
26.6.2	Antitumor Effects of L-Selectin	565

26.6.3	Autoimmune Diseases	566
26.6.4	CD62L in Other Conditions	568
26.7	Oligonucleotide Antagonists IN Therapeutic Applications	569
26.7.1	Monomeric and Multimeric Blockers of Selectins	569
26.7.2	Synthetic and Semisynthetic Oligosaccharides	569
	References	570
27	P-Selectin and Its Ligands	575
	G.S. Gupta	
27.1	Platelet Adhesion and Activation	575
27.2	P-Selectin (GMP-140, PADGEM, CD62): A Member of Selectin Adhesion Family	575
27.2.1	Platelets and Vascular Endothelium Express P-Selectin	575
27.2.2	Human Granule Membrane Protein 140 (GMP-140)/P-Selectin	576
27.2.3	Murine P-Selectin	576
27.2.4	P-Selectin Promoter	577
27.2.5	Structure-Function Studies	578
27.2.6	P-Selectin-Sialyl Lewis ^x Binding Interactions	580
27.2.7	Functions of P-Selectin	580
27.3	P-Selectin Glycoprotein Ligand-1 (PSGL-1)	583
27.3.1	PSGL-1: The Major Ligand for P-Selectin	583
27.3.2	Genomic Organization	585
27.3.3	Specificity of PSGL-1 as Ligand for P-Selectin	585
27.3.4	Structural Polymorphism in PSGL-1 and CAD Risk	585
27.3.5	Carbohydrate Structures on PSGL-1	586
27.3.6	Role of PSGL-1	587
27.4	Other Ligands of P-Selectin	588
	References	590
28	E-Selectin (CD62E) and Associated Adhesion Molecules	593
	G.S. Gupta	
28.1	E-Selectin (Endothelial Leukocyte Adhesion Molecule 1: ELAM-1)	593
28.1.1	Endothelial Cells Express E-Selectin (ELAM-1/CD62E)	593
28.2	E-Selectin Genomic DNA	593
28.2.1	Human E-Selectin	593
28.2.2	E-Selectin Gene in Other Species	594
28.3	E-Selectin Gene Regulation	594
28.3.1	Transcriptional Regulation of CAMs	594
28.3.2	Induction of E-Selectin and Associated CAMs by TNF- α	595
28.3.3	IL-1-Mediated Expression of CAMs	596
28.4	Factors in the Regulation of CAMs	596
28.4.1	NF- κ B: A Dominant Regulator	596
28.4.2	Cyclic AMP Inhibits NF- κ B-Mediated Transcription	597
28.4.3	Peroxisome Proliferator-Activated Receptors	598
28.4.4	Endogenous Factors Regulating CAM Genes	599
28.4.5	Tat Protein Activates Human Endothelial Cells	599
28.4.6	Reactive Oxygen Species (ROS)	599
28.4.7	Role of Hypoxia	600
28.5	Binding Elements in E-Selectin Promoter	600
28.5.1	Transcription Factors Stimulating <i>E-sel</i> Gene	600
28.5.2	CRE/ATF Element or NF-ELAM1	601
28.5.3	HMG-I(Y) Mediates Binding of NF- κ B Complex	602
28.5.4	Phased-Bending of E-Selectin Promoter	602

28.6	E-Selectin Ligands	602
28.6.1	Carbohydrate Ligands (Lewis Antigens)	602
28.6.2	E-Selectin Ligand-1	604
28.6.3	PSGL-1 and Relating Ligands	605
28.6.4	Endoglycan, a Ligand for Vascular Selectins	607
28.6.5	L-Selectin as E-Selectin Ligand	607
28.7	Structural Properties of E-Selectin	608
28.7.1	Soluble E-Selectin: An Asymmetric Monomer	608
28.7.2	Complement Regulatory Domains	608
28.7.3	Three-Dimensional Structure	609
28.8	Functions of E-Selectin	609
28.8.1	Functions in Cell Trafficking	609
28.8.2	E-Selectin in Neutrophil Activation	610
28.8.3	P- and E-Selectin in Differentiation of Hematopoietic Cells	610
28.8.4	Transmembrane Signaling in Endothelial Cells	611
	References	612

Part X C-Type Lectins: Lectin Receptors on NK Cells

29	KLRB Receptor Family and Human Early Activation Antigen (CD69)	619
	Rajesh K. Gupta and G.S. Gupta	
29.1	Lectin Receptors on NK Cell	619
29.1.1	NK Cell Receptors	619
29.1.2	NKC Gene Locus	620
29.2	The Ever-Expanding Ly49 Receptor Gene Family	620
29.2.1	Activating and Inhibitory Receptors	620
29.2.2	Crystal Analysis of CTLD of Ly49I and comparison with Ly29A, NKG2D and MBP-A	622
29.3	NK Cell Receptor Protein 1 (NKR-P1) or KLRB1	623
29.3.1	Ly49 and <i>Nkrp1</i> (<i>Klrbl</i>) Recognition Systems	623
29.3.2	NKR-P1	623
29.4	Human NKR-P1A (CD161)	626
29.4.1	Cellular Localization	626
29.4.2	Transcriptional Regulation	626
29.4.3	Ligands of CD161/ NKR-P1	627
29.4.4	Signaling Pathways	628
29.4.5	Functions of NKR-P1	629
29.5	NKR-P1A in Clinical Disorders	630
29.5.1	Autoimmune Reactions	630
29.5.2	Other Diseases	631
29.5.3	NKR-P1A Receptor (CD161) in Cancer Cells	632
29.6	Human Early Activation Antigen (CD69)	632
29.6.1	Organization of CD69 Gene	633
29.6.2	Src-Dependent Syk Activation of CD69-Mediated Signaling	633
29.6.3	Crystal Analysis of CD69	634
	References	634
30	NKG2 Subfamily C (KLRC)	639
	Rajesh K. Gupta and G.S. Gupta	
30.1	NKG2 Subfamily C (KLRC)	639
30.1.1	NKG2 Gene Family and Structural Organization	639
30.1.2	Human NKG2-A, -B, and -C	640
30.1.3	Murine NKG2A, -B, -C	640

30.1.4	NKG2 Receptors in Monkey	641
30.1.5	NKG2 Receptors in Other Species	642
30.1.6	Inhibitory and Activatory Signals	642
30.2	CD94 (KLRD1)	642
30.2.1	Human CD94 in Multiple Transcripts	642
30.2.2	Mouse CD94	643
30.3	Cellular Sources of NKG2/CD94	643
30.4	The Crystal Analysis of CD94	644
30.4.1	An Intriguing Model for CD94/NKG2 Heterodimer	644
30.5	CD94/NKG2 Complex	646
30.5.1	CD94 and NKG2-A Form a Complex for NK Cells	646
30.6	Acquisition of NK Cell Receptors	646
30.7	Regulation of CD94/NKG2	647
30.7.1	Transcriptional Regulation of NK Cell Receptors	647
30.7.2	Regulation by Cytokines	647
30.8	Functions of CD94/NKG2	648
30.8.1	CD94/NKG2 in Innate and Adaptive Immunity	649
30.8.2	Modulation of Anti-Viral and Anti-Tumoral Responses of γ/δ T Cells	649
30.9	NK Cells in Female Reproductive Tract and Pregnancy	650
30.9.1	Decidual NK Cell Receptors	650
30.10	Signal Transduction by CD94/NKG2	651
30.10.1	Engagement of CD94/NKG2-A by HLA-E and Recruitment of Phosphatases	651
30.11	Ligands for CD94/NKG2	651
30.11.1	HLA-E as Ligand for CD94/NKG2A	651
30.11.2	CD94/NKG2-A Recognises HLA-G1	652
30.11.3	Non-Classical MHC-I Molecule Qa-1b as Ligand	653
30.12	Structure Analysis of CD94-NKG2 Complex	653
30.12.1	Crystal Analysis of NKG2A/CD94: HLA-E Complex	653
30.12.2	CD94-NKG2A Binding to HLA-E	654
30.13	Inhibitory Receptors in Viral Infection	656
30.14	Pathophysiological Role of CD94/NKG2 Complex	658
30.14.1	Polymorphism in NKG2 Genes	658
30.14.2	Phenotypes Associated with Leukemia	658
30.14.3	CD94/NKG2A on NK Cells in T Cell Lymphomas	659
30.14.4	CD94/NKG2 Subtypes on Lymphocytes in Melanoma Lesions	659
30.14.5	Cancers of Female Reproductive Tract	660
30.14.6	Disorders of Immune System	660
	References	661
31	NKG2D Activating Receptor	667
	Rajesh K. Gupta and G.S. Gupta	
31.1	NKG2D Activating Receptor (CD314, Synonyms KLRK1)	667
31.2	Characteristics of NKG2D	667
31.2.1	The Protein	667
31.2.2	Orthologues to Human NKG2D	668
31.3	NKG2D Ligands	668
31.3.1	The Diversity of NKG2D Ligands	668
31.3.2	MHC Class I Chain Related (MIC) Proteins	669

31.3.3	Retinoic Acid Early (RAE) Transcripts	669
31.3.4	Role of NKG2D Ligands	671
31.3.5	Regulation of Ligands	671
31.4	Crystal Structure of NKG2D	672
31.4.1	Structures of NKG2D-Ligand Complexes	672
31.5	DAP10/12 Adapter Proteins	674
31.5.1	DAP10	674
31.5.2	KARAP (DAP12 or TYROBP)	674
31.5.3	Characterization of DAP10 and DAP12	674
31.5.4	NKG2D Receptor Complex and Signaling	675
31.6	Functions of NKG2D	677
31.6.1	Engagement of NKG2D on $\gamma\delta$ T Cells and Cytolytic Activity	677
31.6.2	NKG2D: A Co-stimulatory Receptor for Naive CD8 ⁺ T Cells	678
31.6.3	NKG2D in Cytokine Production	678
31.6.4	Heterogeneity of NK Cells in Umbilical Cord Blood	679
31.7	Cytotoxic Effector Function and Tumor Immune Surveillance	679
31.7.1	Anti-Tumor Activity	679
31.7.2	Immune Evasion Mechanisms	680
31.8	NKG2D in Immune Protection and Inflammatory Disorders	681
31.8.1	NKG2D Response to HCMV	681
31.8.2	HTLV-1-Associated Myelopathy	682
31.8.3	Protection Against Bacteria	682
31.8.4	Autoimmune Disorders	682
31.9	Decidual/Placental NK Cell Receptors in Pregnancy	683
31.10	Regulation of NKG2D Functions	684
31.10.1	NKG2D Induction by Chronic Exposure to NKG2D Ligand	684
31.10.2	Effects of Cytokines and Other Factors	685
31.11	Role in Immunotherapy	686
	References	686
32	KLRC4, KLRG1, and Natural Cytotoxicity Receptors	693
	Rajesh K. Gupta and G.S. Gupta	
32.1	Killer Cell Lectin-Like Receptor F-1 (NKG2F/KLRC4/CLECSF/NKp80)	693
32.1.1	NKp80 or Killer Cell Lectin-Like Receptor Subfamily F-Member 1 (KLRF1)	693
32.1.2	NKp80/KLRF1 Associates with DAP12	694
32.2	Activation-Induced C-Type Lectin (CLECSF2): Ligand for NKp80	694
32.3	KLRG1 (Rat MAFA/CLEC15A or Mouse 2F1-Ag)	695
32.3.1	Mast Cell Function-Associated Antigen (MAFA)	695
32.3.2	MAFA Is a Lectin	695
32.3.3	Interactions of MAFA with Fc ϵ R	695
32.3.4	MAFA Gene	696
32.4	KLRG1 (OR 2F1-AG): A Mouse Homologue of MAFA	696
32.4.1	KLRG1: A Mouse Homologue of MAFA	696
32.4.2	NK Cell Maturation and Homeostasis Is Linked to KLRG1 Up-Regulation	698
32.4.3	Cadherins as Ligands of KLRG1	699
32.5	MAFA-Like Receptor in Human NK Cell (MAFA-L)	699
32.5.1	Characteristics and Biological Properties	699
32.6	Killer Cell Lectin Like Receptor Subfamily E, Member 1 (KLRE1)	699
32.7	KLRL1 from Human and Mouse DCs	700

32.8	Natural Cytotoxicity Receptors	701
32.8.1	NK Cell Triggering: The Activating Receptors	701
32.8.2	Activating Receptors and Their Ligands	701
	References	703

Part XI C-Type Lectins: Endocytic Receptors

33	Asialoglycoprotein Receptor and the Macrophage Galactose-Type Lectin . . .	709
	Anita Gupta	
33.1	Asialoglycoprotein Receptor: The First Animal Lectin Discovered	709
33.2	Rat Asialoglycoprotein Receptor	709
33.2.1	Characteristics	709
33.3	Human Asialoglycoprotein Receptor	710
33.3.1	Structural Characteristics	710
33.4	Ligand Binding Properties of ASGP-R	711
33.4.1	Interaction with Viruses	712
33.5	The Crystal Structure of H1-CRD	713
33.5.1	The Sugar Binding Site of H1-CRD	713
33.5.2	Sugar Binding to H1-CRD	714
33.6	Physiological Functions	715
33.6.1	Impact of ASGP-R Deficiency on the Development of Liver Injury	715
33.7	ASGP-R: A Marker for Autoimmune Hepatitis and Liver Damage	715
33.7.1	Autoimmune Hepatitis	715
33.7.2	Hepatocellular Carcinoma	716
33.7.3	Extra-Hepatic ASGP-R	716
33.8	ASGP-R: A Model Protein for Endocytosis	716
33.9	ASGP-R for Targeting Hepatocytes	717
33.10	Macrophage Galactose-Type Lectin (MGL) (CD301)	718
33.10.1	Human MGL (CD 301)	718
33.10.2	Murine MGL1/MGL2 (CD301)	718
33.10.3	Ligands of MGL	719
33.10.4	Functions of MGL	720
	References	721
34	Dectin-1 Receptor Family	725
	Rajesh K. Gupta and G.S. Gupta	
34.1	Natural Killer Gene Complex (NKC)	725
34.2	β -Glucan Receptor (Dectin 1) (CLEC7A or CLECSF12)	725
34.2.1	Characterization of β -Glucan Receptor (Dectin 1)	725
34.2.2	Crystal Structure of Dectin-1	727
34.2.3	Interactions of Dectin-1 with Natural or Synthetic Glucans	727
34.2.4	Regulation of Dectin-1	727
34.2.5	Signaling Pathways by Dectin-1	728
34.2.6	Functions of Dectin-1	729
34.2.7	Genetic Polymorphism in Relation to Pathology	730
34.3	The C-Type Lectin-Like Protein-1 (CLEC-1) or CLEC-1A	731
34.3.1	<i>CLEC-1</i> Gene	731
34.4	CLEC-18 or the C-Type Lectin-Like Protein-2 (CLEC-2) or CLEC1B	731
34.4.1	Characterization	731
34.4.2	Ligands for CLEC-2	732
34.4.3	Crystal Structure of CLEC-2	733

34.4.4	Functions of CLEC-2	733
34.4.5	CLEC-2 Signaling	734
34.5	CLEC9A (DNDR-1)	734
34.6	Myeloid Inhibitory C-Type Lectin-Like Receptor (MICL/CLEC12A)	735
34.7	CLEC12B or Macrophage Antigen H	735
34.8	CLECSF7 (CD303)	735
34.9	Lectin-Like Oxidized LDL Receptor (LOX-1) (CLEC8A)	736
34.9.1	General Features of LOX-1	736
34.9.2	LOX-1 Gene in Human	737
34.9.3	Ligands for LOX-1	738
34.9.4	Structural Analysis	738
34.9.5	Functions of LOX-1	740
34.9.6	LOX-1 and Pathophysiology	741
34.9.7	Macrophage Differentiation to Foam Cells	742
	References	743
35	Dendritic Cell Lectin Receptors (Dectin-2 Receptors Family)	749
	Rajesh K. Gupta and G.S. Gupta	
35.1	Dendritic Cells	749
35.2	Dendritic Cell-Associated Lectins	750
35.2.1	Type-I and Type-II Surface Lectins on DC	750
35.3	Macrophage Mannose Receptor (CD206) on DC	750
35.3.1	Expression and Characteristics	750
35.3.2	Functions of Mannose Receptor in DC	752
35.4	DEC-205	753
35.5	Langerin: A C-Type Lectin on Langerhans Cells	753
35.5.1	Human Langerin (CD207)	753
35.5.2	Mouse Langerin: Homology to Human Langerin	754
35.5.3	Ligands of Langerin	755
35.5.4	Functions of Langerin	755
35.6	DC-SIGN and DC-SIGNR on DCs	756
35.7	Dectin-2 Cluster in Natural Killer Gene Complex (NKG)	757
35.7.1	Natural Killer Gene Complex	757
35.7.2	Antigen Presenting Lectin-Like Receptor Complex (APLEC)	759
35.8	Dectin-2 (CLECF4N)	759
35.8.1	Characteristics	759
35.8.2	Ligands of Dectin-2	760
35.9	The DC Immunoreceptor and DC-Immunoactivating Receptor	762
35.9.1	Dendritic Cell Immunoreceptor (DCIR) (CLECF6): Characterization	762
35.9.2	Dendritic Cell Immunoactivating Receptor (DCAR)	764
35.10	Macrophage-Inducible C-Type Lectin (Mincle)	764
35.10.1	Recognition of Pathogens	765
35.10.2	Recognition of Mycobacterial Glycolipid, Trehalose Dimycolate	765
35.11	Blood Dendritic Cell Antigen-2 (BDCA-2) (CLEC-4C)	765
35.11.1	BDCA-2: A Plasmacytoid DCs (PDCs)-Specific Lectin	765
35.11.2	Characterization	765
35.11.3	BDCA-2 Signals in PDC via a BCR-Like Signalosome	766
35.11.4	Functions of BDCA-2	766
35.12	CLECSF8	767
35.13	Macrophage Galactose/N-acetylgalactosamine Lectin (MGL)	767
	References	767

36 DC-SIGN Family of Receptors	773
Rajesh K. Gupta and G.S. Gupta	
36.1 DC-SIGN (CD209) Family of Receptors	773
36.1.1 CD209 Family Genes in Sub-Human Primates	773
36.2 DC-SIGN (CD209): An Adhesion Molecule on Dendritic Cells	774
36.3 Ligands of DC-SIGN	775
36.3.1 Carbohydrates as Ligands of DC-SIGN	775
36.4 Structure of DC-SIGN	775
36.4.1 Neck-Domains	775
36.4.2 Crystal Structure of DC-SIGN (CD209) and DC-SIGNR (CD299)	776
36.5 DC-SIGN versus DC-SIGN-RELATED RECEPTOR [DC-SIGNR or L-SIGN (CD 209)/LSEctin] (Refer Section 36.9)	777
36.5.1 DC-SIGN Similarities with DC-SIGNR/L-SIGN/LSEctin	777
36.5.2 Domain Organization of DC-SIGN and DC-SIGNR	778
36.5.3 Differences Between DC-SIGN and DC-SIGNR/L-SIGN	778
36.5.4 Recognition of Oligosaccharides by DC-SIGN and DC-SIGNR	779
36.5.5 Extended Neck Regions of DC-SIGN and DC-SIGNR	780
36.5.6 Signaling by DC-SIGN through Raf-1	781
36.6 Functions of DC-SIGN	781
36.6.1 DC-SIGN Supports Immune Response	781
36.6.2 DC-SIGN Recognizes Pathogens	782
36.6.3 DC-SIGN as Receptor for Viruses	783
36.6.4 HIV-1 gp120 and Other Viral Envelope Glycoproteins	783
36.7 Subversion and Immune Escape Activities of DC-SIGN	785
36.7.1 The entry and dissemination of viruses can be mediated by DC-SIGN	785
36.7.2 DC-SIGN and Escape of Tumors	785
36.7.3 <i>Mycobacterial</i> Carbohydrates as Ligands of DC-SIGN, L-SIGN and SIGNR1	786
36.7.4 Decreased Pathology of Human DC-SIGN Transgenic Mice During <i>Mycobacterial</i> Infection	787
36.7.5 Genomic Polymorphism of DC-SIGN (CD209) and Consequences	787
36.8 SIGNR1 (CD209b): The Murine Homologues of DC-SIGN	789
36.8.1 Characterization	789
36.8.2 Functions	790
36.9 Liver and Lymph Node Sinusoidal Endothelial Cell C-Type Lectin (LSEctin) (or CLEC4G or L-SIGN or CD209L)	791
36.9.1 Characterization and Localization	791
36.9.2 Ligands of LSEctin	792
36.9.3 Functions	792
36.9.4 Role in Pathology	793
References	793

Part XII C-Type Lectins: Proteoglycans

37	Lectican Protein Family	801
	G.S. Gupta	
37.1	Proteoglycans	801
37.1.1	Nomenclature of PGs	801
37.1.2	Glycosaminoglycans	802
37.1.3	Chondroitin	803
37.1.4	Heparan Sulfate Proteoglycans (HSPG)	805
37.2	Proteoglycans in Tissues	805
37.3	Hyaluronan: Proteoglycan Binding Link Proteins	807
37.4	Lecticans (Hyalectans)	807
37.5	Cartilage Proteoglycan: Aggrecan	808
37.5.1	Skeletogenesis	808
37.5.2	Human Aggrecan	808
37.5.3	Rat Aggrecan	810
37.5.4	Mouse Aggrecan	812
37.5.5	Chick Aggrecan	812
37.6	Versican or Chondroitin Sulfate Proteoglycan Core Protein 2	812
37.6.1	Expression	813
37.6.2	Structure	814
37.6.3	Interactions of Versican	814
37.6.4	Functions	815
37.7	Pathologies Associated with PGS	816
37.7.1	Proteoglycans Facilitate Lipid Accumulation in Arterial Wall	816
37.8	Diseases of Aggrecan Insufficiency	817
37.8.1	Aggrecanase-Mediated Cartilage Degradation	817
37.8.2	A Mutation in Aggrecan Gene Causes Spondyloepiphyseal Dysplasia	818
37.9	Expression of Proteoglycans in Carcinogenesis	818
37.10	Regulation of Proteoglycans	819
37.11	CD44: A Major Hyaluronan Receptor	819
37.11.1	CD44: A Hyaluronan Receptor	819
37.11.2	Hyaluronan Binding Sites in CD44	819
37.11.3	CD44 in Cancer	820
	References	820
38	Proteoglycans of the Central Nervous System	825
	G.S. Gupta	
38.1	Proteoglycans in Central Nervous System	825
38.1.1	Large Proteoglycans in Brain	825
38.1.2	Ligands of Lecticans	826
38.2	Neurocan	828
38.2.1	Cellular Sites of Synthesis	828
38.2.2	Characterization	828
38.2.3	Ligand Interactions	829
38.3	Brevican	830
38.3.1	Characterization	830
38.3.2	Murine Brevican Gene	830
38.4	Hyaluronan: Proteoglycan Binding Link Protein	831
38.4.1	Cartilage link protein 1 and Brain Link Proteins	831
38.4.2	Brain Enriched Hyaluronan Binding (BEHAB)/Brevican	832
38.5	Proteolytic Cleavage of Brevican	832
38.6	Proteoglycans in Sensory Organs	833

38.7	Functions of Proteoglycans in CNS	834
38.7.1	Functions of Chondroitin Sulphate Proteoglycans	834
38.7.2	Functions of Brevican and Neurocan in CNS	835
38.7.3	Neurocan in Embryonic Chick Brain	836
38.8	Chondroitin Sulfate Proteoglycans in CNS Injury Response	836
38.8.1	CS-PGs in CNS in Response to Injury	836
38.8.2	Glial Scar and CNS Repair	838
38.9	Other Proteoglycans in CNS	838
38.10	Regulation of Proteoglycans in CNS	839
38.10.1	Growth Factors and Cytokine Regulate CS-PGs by Astrocytes	839
38.10.2	Decorin Suppresses PGs Expression	839
	References	840

Part XIII C-Type Lectins: Emerging Groups of C-Type Lectins

39	Regenerating (Reg) Gene Family	847
	G.S. Gupta	
39.1	The Regenerating Gene Family	847
39.2	Regenerating (<i>Reg</i>) Gene Products	847
39.3	Reg 1	848
39.3.1	Tissue Expression	848
39.3.2	Gastric Mucosal Cells	849
39.3.3	Ectopic Expression	849
39.3.4	Reg Protein	850
39.3.5	<i>REGIA (Reg Iα)</i> Gene in Human Pancreas	850
39.3.6	<i>REGIB (Reg Iβ)</i> Gene in Human Pancreas	852
39.4	Pancreatic Stone Protein/Lithostathine (PSP/LIT)	852
39.4.1	Characterization	852
39.4.2	3D-Structure	853
39.4.3	Secretory Forms of PSP	853
39.4.4	Functions of PSP/LIT	854
39.5	Pancreatic Thread Protein	855
39.5.1	Pancreatic Thread Proteins (PTPs)	855
39.5.2	Neuronal Thread Proteins	856
39.5.3	Pancreatic Proteins Form Fibrillar Structures upon Tryptic Activation	856
39.6	<i>REG-II/REG-2/PAP-I</i>	857
39.7	<i>Reg-III</i>	858
39.7.1	Murine <i>Reg-IIIα</i> , <i>Reg-IIIβ</i> , <i>Reg-IIIγ</i> , and <i>Reg-IIIδ</i> Genes	858
39.7.2	Human <i>Reg-III</i> or <i>HIP/PAP</i>	859
39.8	Rat PAPs	860
39.8.1	Three Forms of PAP in Rat	860
39.8.2	<i>PAP-I/Reg-2 Protein (or HIP, p23)</i>	861
39.8.3	<i>PAP-II/PAP2</i>	861
39.8.4	<i>PAP-III</i>	862
39.9	Functions of PAP	863
39.9.1	<i>PAP: A Multifunctional Protein</i>	863
39.9.2	<i>PAP in Bacterial Aggregation</i>	863
39.9.3	<i>PAP-I: An Anti-inflammatory Cytokine</i>	863
39.10	Pancreatitis Associated Protein (PAP)/Hepatocarcinoma-Intestine Pancreas (HIP)	865
39.10.1	<i>HIP Similarity to PAP</i>	865
39.10.2	<i>Characterization of HIP/PAP</i>	866

39.10.3	PAP Ligands (PAP Interactions)	867
39.10.4	Crystal Structure of human PAP (hPAP)	867
39.10.5	Expression of PAP	867
39.10.6	Similarity of PAP to Peptide 23 from Pituitary	869
39.10.7	Serum PAP: An Indicator of Pancreatic Function	870
39.11	Reg IV (RELP)	870
39.11.1	Tissue Expression	870
39.12	Islet Neogenesis-Associated Protein (INGAP) in Hamster	871
39.12.1	Characterization	871
39.12.2	Properties of Pentadecapeptide from INGAP	872
	References	873
40	Emerging Groups of C-Type Lectins	881
	G.S. Gupta	
40.1	Layilin Group of C-Type Lectins (Group VIII of CTLDS)	881
40.1.1	Layilin: A Hyaluronan Receptor	881
40.1.2	Interactions of Layilin	881
40.1.3	Functions of Layilin	881
40.1.4	Chondrolectin (CHODL)	882
40.2	Tetranectin Group of Lectins (Group IX of CTLDS)	882
40.2.1	Tetranectin	883
40.2.2	Cell and Tissue Distribution	884
40.2.3	Interactions of Tetranectin	884
40.2.4	Crystal Structure of Tetranectin	885
40.2.5	Functions of Tetranectin	886
40.2.6	Association of TN with Diseases	887
40.2.7	Cartilage-Derived C-Type Lectin (CLECSF1)	888
40.2.8	Stem Cell Growth Factor (SCGF): Tetranectin Homologous Protein	888
40.3	Attractin Group of CTLDS (Group XI)	888
40.3.1	Secreted and Membrane Attractins	888
40.3.2	Attractin has Dipeptidyl Peptidase IV Activity?	889
40.3.3	Attractin-Like Protein	889
40.3.4	Functions of Attractin	890
40.3.5	Genetic and Phenotypic Studies of <i>Mahogany/Attractin</i> Gene	892
40.3.6	Therapeutic Applications of ATRN/ <i>Mahogany</i> Gene Products	894
40.4	Eosinophil Major Basic Protein 1 (EMBP1) (Group XII of CTLDS)	894
40.4.1	Characterization of EMBP	894
40.4.2	Functions of EMBP	895
40.4.3	Crystal Structure of EMBP	895
40.4.4	DEC-205-Associated C-Type Lectin (DCL)-1	895
40.5	Integral Membrane Protein, Deleted in Digeorge Syndrome (IDD) (Group XIII of CTLDS)	896
40.5.1	DiGeorge Syndrome Critical Region 2 (DGCR2)	896
	References	896
41	Family of CD93 and Recently Discovered Groups of CTLDS	901
	G.S. Gupta	
41.1	Family of CD93	901
41.2	CD93 or C1q Receptor (C1qRp): A Receptor for Complement C1q	901
41.2.1	CD93 Is Identical to C1qRp	901
41.2.2	Characterization of CD93/C1qRp	902
41.2.3	Two Types of Cell Surface C1q-Binding Proteins (C1qR)	902
41.2.4	Tissue Expression and Regulation of CD93/C1qRp	903

41.2.5	Functions	904
41.2.6	CD93 in Pathogenesis of SLE	904
41.3	Murine Homologue of Human C1qRp (AA4)	905
41.4	The gC1qR (p33, p32, C1qBP, TAP)	906
41.4.1	A Multi-Multifunctional Protein - Binding with C1q	906
41.4.2	Human gC1qR/p32 (C1qBP) Gene	907
41.4.3	Ligand Interactions	908
41.4.4	Role in Pathology	909
41.5	Thrombomodulin	910
41.5.1	Localization	910
41.5.2	Characteristics	910
41.5.3	Regulation of TM Activity	910
41.5.4	Structure-Function Relations - Binding to Thrombin	911
41.5.5	The Crystal Structure	913
41.5.6	Functions	914
41.5.7	Abnormalities Associated with Thrombomodulin Deficiency	916
41.6	Endosialin (Tumor Endothelial Marker-1 or CD248)	917
41.6.1	A Marker of Tumor Endothelium	917
41.6.2	Interactions with Ligands	918
41.6.3	Functions	919
41.7	Bimlec (DEC 205 Associated C-type lectin-1 or DCL-1) or (CD302) (Group XV of CTLD)	920
41.8	Proteins Containing SCP, EGF, EGF and CTLD (SEEC) (Group XVI of CTLD)	920
41.8.1	Nematocyst Outer Wall Antigen (NOWA)	921
41.8.2	The Cysteine-Rich Secretory Proteins (CRISP) Super-Family	921
41.9	Calx- <i>b</i> and CTLD Containing Protein (CBCP) (Group XVII of CTLD)	922
41.9.1	CBCP/Frem1/QBRICK	922
41.9.2	Frem3	924
41.9.3	Zebrafish Orthologues of FRAS1, FREM1, or FREM2	924
	References	924

Part XIV Clinical Significance of Animal Lectins

42	MBL Deficiency as Risk of Infection and Autoimmunity	933
	Anita Gupta	
42.1	Pathogen Recognition	933
42.1.1	MBL Characteristics	933
42.1.2	Pathogen Recognition and Role in Innate Immunity	933
42.2	MBL Deficiency as Risk of Infection and Autoimmunity	935
42.2.1	MBL Deficiency and Genotyping	935
42.2.2	MBL and Viral Infections	938
42.3	Autoimmune and Inflammatory Diseases	939
42.3.1	MBL Gene in Rheumatoid Arthritis	939
42.3.2	Systemic Lupus Erythematosus	940
42.3.3	Systemic Inflammatory Response Syndrome/Sepsis	941
42.3.4	MBL and Inflammatory Bowel Diseases	942
42.3.5	Rheumatic Heart Disease	943
42.3.6	MBL in Cardio-Vascular Complications	944
42.3.7	Other Inflammatory Disorders	945
42.4	Significance of MBL Gene in Transplantation	946
42.5	MBL in Tumorigenesis	947
42.5.1	Polymorphisms in the Promoter	947
42.5.2	MBL Binding with Tumor Cells	947

42.6	Complications Associated with Chemotherapy	947
42.6.1	Neutropenia	947
42.6.2	Animal Studies	948
42.7	MBL: A Reconstitution Therapy	949
	References	949
43	Pulmonary Collectins in Diagnosis and Prevention of Lung Diseases	955
	Anita Gupta	
43.1	Pulmonary Surfactant	955
43.2	SP-A and SP-D in Interstitial Lung Disease	955
43.2.1	Pneumonitis	955
43.2.2	Interstitial Pneumonia (IP)	956
43.2.3	ILD Due to Inhaled Substances	957
43.2.4	Idiopathic Pulmonary Fibrosis	957
43.2.5	Cystic Fibrosis	958
43.2.6	Familial Interstitial Lung Disease	959
43.3	Connective Tissue Disorders	959
43.3.1	Systemic Sclerosis	959
43.3.2	Sarcoidosis	960
43.4	Pulmonary Alveolar Proteinosis	960
43.4.1	Idiopathic Pulmonary Alveolar Proteinosis	960
43.4.2	Structural Changes in SPs in PAP	961
43.5	Respiratory-Distress Syndrome and Acute Lung Injury	961
43.5.1	ARDS and Acute Lung Injury	961
43.5.2	Bronchopulmonary Dysplasia (BPD)	962
43.6	Chronic Obstructive Pulmonary Disease (COPD)	963
43.6.1	COPD as a Group of Diseases	963
43.6.2	Emphysema	964
43.6.3	Allergic Disorders	964
43.6.4	Interactions of SP-A and SP-D with Pathogens and Infectious Diseases	965
43.7	Pulmonary Tuberculosis	966
43.7.1	Enhanced Phagocytosis of <i>M. tuberculosis</i> by SP-A	966
43.7.2	SP-A Modulates Inflammatory Response in AΦs During Tuberculosis	967
43.7.3	Marker Alleles in <i>M. tuberculosis</i>	968
43.7.4	Interaction of SP-D with <i>M. tuberculosis</i>	968
43.7.5	Association of SPs with Diabetes	969
43.8	Expression of SPs in Lung Cancer	969
43.8.1	Non-Small-Cell Lung Carcinoma (NSCLC)	969
43.9	Other Inflammatory Disorders	971
43.9.1	Airway Inflammation in Children with Tracheostomy	971
43.9.2	Surfactant Proteins in Non-ILD Pulmonary Conditions	971
43.10	DNA Polymorphisms in SPs and Pulmonary Diseases	972
43.10.1	Association Between SP-A Gene Polymorphisms and RDS	972
43.10.2	SP-A and SP-B as Interactive Genetic Determinants of Neonatal RDS	973
43.10.3	RDS in Premature Infants	973
43.10.4	Gene Polymorphism in Patients of High-altitude Pulmonary Edema	973
43.10.5	SNPs in Pulmonary Diseases	974
43.10.6	Allergic Bronchopulmonary Aspergillosis and Chronic Cavitary Pulmonary Aspergillosis (CCPA)	974
43.10.7	Autoreactivity Against SP-A and Rheumatoid Arthritis	975

43.11	Inhibition of SP-A Function by Oxidation Intermediates of Nitrite	975
43.11.1	Protein Oxidation by Chronic Pulmonary Diseases	975
43.11.2	Oxidation Intermediates of Nitrite	976
43.11.3	BPD Treatment with Inhaled NO	976
43.12	Congenital Diaphragmatic Hernia	976
43.13	Protective Effects of SP-A and SP-D on Transplants	977
43.14	Therapeutic Effects of SP-A, SP-D and Their Chimeras	977
43.14.1	SP-A Effects on Inflammation of Mite-sensitized Mice	977
43.14.2	SP-D Increases Apoptosis in Eosinophils of Asthmatics	977
43.14.3	Targeting of Pathogens to Neutrophils Via Chimeric SP-D/Anti-CD89 Protein	978
43.14.4	Anti-IAV and Opsonic Activity of Multimerized Chimeras of rSP-D	978
43.15	Lessons from SP-A and SP-D Deficient Mice	979
	References	980
44	Selectins and Associated Adhesion Proteins in Inflammatory disorders	991
	G.S. Gupta	
44.1	Inflammation	991
44.2	Cell Adhesion Molecules	991
44.2.1	Selectins	992
44.3	Atherothrombosis	992
44.3.1	Venous Thrombosis	992
44.3.2	Arterial Thrombosis	993
44.3.3	Thrombogenesis in Atrial Fibrillation	993
44.3.4	Atherosclerosis	993
44.3.5	Myocardial Infarction	996
44.3.6	Atherosclerotic Ischemic Stroke	997
44.3.7	Hypertension	998
44.3.8	Reperfusion Injury	998
44.4	CAMS in Allergic Inflammation	998
44.4.1	Dermal Disorders	998
44.4.2	Rhinitis and Nasal Polyposis	999
44.4.3	Lung Injury	999
44.4.4	Bronchial Asthma and Human Rhinovirus	999
44.5	Autoimmune Diseases	1000
44.5.1	Endothelial Dysfunction in Diabetes (Type 1 Diabetes)	1000
44.5.2	Rheumatic Diseases	1001
44.5.3	Rheumatoid Arthritis	1001
44.5.4	Other Autoimmune Disorders	1002
44.6	CAMs in System Related Disorders	1003
44.6.1	Gastric Diseases	1003
44.6.2	Liver Diseases	1004
44.6.3	Neuro/Muscular Disorders	1004
44.6.4	Acute Pancreatitis	1005
44.6.5	Renal Failure	1005
44.6.6	Other Inflammatory Disorders	1005
44.6.7	Inflammation in Hereditary Diseases	1006
44.7	Role of CAMs in Cancer	1006
44.7.1	Selectin Ligands in Cancer cells	1007
44.7.2	E-Selectin-Induced Angiogenesis	1007
44.7.3	E-Selectin in Cancer Cells	1007
44.7.4	Metastatic Spreading	1009
44.7.5	Survival Benefits of Heparin	1011

44.8	Adhesion Proteins in Transplantation	1012
44.9	Inflammation During Infection	1013
44.9.1	Microbial Pathogens	1013
44.9.2	Yeasts and Fungi	1014
44.9.3	Parasites and Amoeba	1014
44.10	Action of Drugs and Physical Factors on CAMS	1015
44.10.1	Inhibitors of Gene Transcription	1015
44.10.2	Anti-NF- κ B Reagents	1015
44.10.3	Strategies to Combat Atherogenesis and Venous Thrombosis	1016
44.10.4	Anti-inflammatory Drugs	1017
	References	1018
45	Polycystins and Autosomal Polycystic Kidney Disease	1027
	G.S. Gupta	
45.1	Polycystic Kidney Disease Genes	1027
45.1.1	Regulatory Elements in Promoter Regions	1028
45.2	Polycystins: The Products of PKD Genes	1028
45.2.1	Polycystins	1028
45.2.2	Polycystin-1 (TRPP1) with a C-type Lectin Domain	1028
45.2.3	Polycystin-2 (TRPP2)	1030
45.2.4	Interactions of Polycystins	1031
45.2.5	Tissue and Sub-Cellular Distribution of Polycystins	1031
45.3	Functions of Polycystin-1 and Polycystin-2	1032
45.3.1	Polycystin-1 and Polycystin-2 Function Together	1032
45.3.2	Cell-Cell and Cell-Matrix Adhesion	1032
45.3.3	Role in Ciliary Signaling	1033
45.3.4	Cilia and Cell Cycle	1034
45.3.5	Polycystins and Sperm Physiology	1034
45.4	Autosomal Dominant Polycystic Kidney Disease	1034
45.4.1	Mutations in <i>PKD1</i> and <i>PKD2</i> and Association of Polycystic Kidney Disease	1034
45.4.2	Proliferation and Branching Morphogenesis in Kidney Epithelial Cells	1035
	References	1035
46	Endogenous Lectins as Drug Targets	1039
	Rajesh K. Gupta and Anita Gupta	
46.1	Targeting of Mannose-6-Phosphate Receptors and Applications in Human Diseases	1039
46.1.1	Lysosomal Storage Diseases	1039
46.1.2	Enzyme Replacement Therapy (ERT)	1040
46.1.3	M6PR-Mediated Transport Across Blood-Brain Barrier	1042
46.1.4	Other Approaches using CI-MPR as Target	1045
46.2	Cell Targeting Based on Mannan-Lectin Interactions	1045
46.2.1	Receptor-Mediated Uptake of Mannan-Coated Particles (Direct Targeting)	1046
46.2.2	Polymeric Glyco-Conjugates as Carriers	1046
46.2.3	Mannosylated Liposomes in Gene Delivery	1047
46.2.4	DC-Targeted Vaccines	1049
46.3	Asialoglycoprotein Receptor (ASGP-R) for Targeted Drug Delivery	1051
46.3.1	Targeting Hepatocytes	1051
46.4	Siglecs as Targets for Immunotherapy	1052

46.4.1	Anti-CD33-Antibody-Based Therapy of Human Leukemia	1052
46.4.2	CD22 Antibodies as Carrier of Drugs	1053
46.4.3	Immunogenic Peptides	1053
46.4.4	Blocking of CD33 Responses by SOCS3	1053
	References	1053
	About the Author	1059
	Index	1061